Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CRM197 is a genetically detoxified, non-toxic mutant of diphtheria toxin. It is widely used as a carrier protein in conjugate vaccines to enhance the immunogenicity of polysaccharides and haptens, which are otherwise poorly immunogenic. It retains strong immunostimulant properties, making it effective for use in vaccines as an antigen carrier. There is also emerging interest in potential antitumor applications due to its ability to bind soluble HB-EGF—a factor overexpressed in some cancers.
Converts T-cell independent antigens into T-cell dependent antigens, facilitating robust immune responses to conjugated antigens.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Diphtheria Toxin Variant CRM197 (CRM197).